While AD biomarkers, such as cerebrospinal fluid (CSF) biomarkers and positron emission tomography (PET) imaging of amyloid-β (Aβ) and tau, have advanced diagnostic capabilities, their widespread use is hampered by their invasiveness, high cost and limited availability [5]. Here, MAPT is linked to Alzheimer disease.